[A20-79] Secukinumab (non-radiographic axial spondyloarthritis) - Benefit assessment according to §35a Social Code Book V
Last updated 01.12.2020
Project no.:
A20-79
Commission:
Commission awarded on 28.08.2020 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Muscles, bones and joints
Indication:
| Adults with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation who have responded inadequately to NSAIDs |
Result of dossier assessment:
| Added benefit not proven due to a lack of study data |
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A20-78 | Secukinumab (plaque psoriasis in children and adolescents) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A17-08 | Secukinumab (plaque psoriasis) - Benefit assessment according to §35a Social Code Book V (new scientific findings) | Commission completed |
| A15-53 | Secukinumab (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A15-20 | Secukinumab - Benefit assessment according to §35a Social Code Book V (dossier assessment) | Commission completed |
| A20-80 | Secukinumab (psoriatic arthritis) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A22-69 | Secukinumab (enthesitis-associated arthritis) – Benefit assessment according to § 35a SGB V | Commission completed |
| A22-68 | Secukinumab (juvenile psoriatic arthritis) – Benefit assessment according to §35a Social Code Book V | Commission completed |